When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Giant cell arteritis

Last reviewed: 30 Oct 2023
Last updated: 02 Aug 2023



History and exam

Key diagnostic factors

  • headache
  • polymyalgia rheumatica symptoms
  • extremity claudication
  • other cranial artery abnormalities
  • loss of vision
  • jaw claudication
  • superficial temporal artery tenderness, thickening, or nodularity
  • absent temporal artery pulse
  • abnormal fundoscopy
More key diagnostic factors

Other diagnostic factors

  • systemic symptoms
  • neurologic symptoms
  • cough, sore throat, hoarseness
  • bruit on auscultation
  • asymmetric blood pressure
  • shoulder tenderness
  • limited active range of movement of shoulders and hips
  • wrist and knee swelling
Other diagnostic factors

Risk factors

  • age ≥50 years
  • female sex
  • genetic factors
  • smoking
  • atherosclerosis
  • environmental factors
More risk factors

Diagnostic investigations

1st investigations to order

  • ESR
  • CRP
  • CBC
  • LFTs
  • temporal artery biopsy
  • temporal artery ultrasound
More 1st investigations to order

Investigations to consider

  • noninvasive vascular imaging
More investigations to consider

Emerging tests

  • FDG-PET scan of head to mid-thigh
  • ultrasound scan of the upper extremity arteries

Treatment algorithm


suspected GCA


confirmed GCA



Kenneth J. Warrington, MD
Kenneth J. Warrington

Professor of Medicine

Mayo Clinic College of Medicine




KJW’s employer receives payments from Eli Lilly and Kiniksa for his role as investigator in giant cell arteritis clinical trials. KJW has conducted consulting work for Sanofi, and received compensation from Roche/Genentech for lecturing. KJW is an author of a number of references cited in this topic.


Dr Kenneth J. Warrington wishes to gratefully acknowledge Dr Eric L. Matteson, a previous contributor to this topic.


ELM’s employer has received payments from Bristol Meyers Squibb and GlaxoSmithKline for his role as investigator in giant cell arteritis clinical trials; from Novartis for his role in polymyalgia rheumatica clinical trials; and from GlaxoSmithKline for his role as an advisory consultant. ELM is an author and editor for Up To Date and Paradigm, as well as an author of a number of references cited in this topic.

Peer reviewers

Anisha B. Dua, MD, MPH

Associate Professor

Northwestern University Feinberg School of Medicine




ABD declares they have paid consultancies from Amgen, Abbvie, Novartis, GSK and Sanofi. ABD is on the board of directors for the Vasculitis Foundation.

Kuntal Chakravarty, FRCP (London), FRCP (Glasgow), FRCP (Ireland), FACP (USA), FACR (USA)

Consultant Rheumatologist

BHRT University Hospital

Queen’s Hospital




KC declares that he has no competing interests.

  • Differentials

    • Polymyalgia rheumatica (PMR)
    • Solid organ cancers and hematologic malignancies
    • Takayasu arteritis (TA)
    More Differentials
  • Guidelines

    • American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for giant cell arteritis
    • Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis
    More Guidelines
  • Patient leaflets

    Giant cell arteritis

    More Patient leaflets
  • Videos

    Venepuncture and phlebotomy: animated demonstration

    More videos
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer